This article is more than 5 years old. Information may no longer be current.

FDA OKs new drug application for Topicort to treat plaque psoriasis

The FDA has approved Taro Pharmaceutical Industries’ new drug application for its topical corticosteroid spray for treating plaque psoriasis, the company announced.

Topicort (desoximetasone) topical spray 0.25% is indicated for plaque psoriasis in patients aged 18 years and older, according to a Taro press release.

Nationwide sales of corticosteroid sprays generate $100 million annually, Taro reported.

Taro already markets four other Topicort prescribing options, including creams, gel and ointment, for the treatment of scalp psoriasis and dermatitis.